Evidence map›Paper›PMID 21673011›Full record

ArticleMolecular cancer research : MCR2011

Osteopontin stimulates preneoplastic cellular proliferation through activation of the MAPK pathway.

Xianmin Luo, Megan K Ruhland, Ermira Pazolli, Anne C Lind, Sheila A Stewart

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cancer research : MCR, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 59 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Fibroblasts in the Tumor Microenvironment: Shield or Spear?International journal of molecular sciences · 2018
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Role of osteopontin in the pathophysiology of cancer.Matrix biology : journal of the International Society for Matrix Biology · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Xianmin LuoDepartment of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Megan K Ruhland
Ermira Pazolli
Anne C Lind
Sheila A Stewart
Washington University in St. Louis · US

Funding

THE ROLE OF FIBROBLAST-DERIVED OSTEOPONTIN IN TUMORIGENESISR01CA130919 · NCI · WASHINGTON UNIVERSITY · PI STEWART, SHEILA A · 2009 to 2013
$1.2M
NCI NIH HHS 5 R01 CA130919NCI NIH HHS R01 CA130919
6 · The paper itself

Abstract

Alterations in the microenvironment collaborate with cell autonomous mutations during the transformation process. Indeed, cancer-associated fibroblasts and senescent fibroblasts stimulate tumorigenesis in xenograft models. Because senescent fibroblasts accumulate with age, these findings suggest that they contribute to age-related increases in tumorigenesis. Previously we showed that senescence-associated stromal-derived osteopontin contributes to preneoplastic cell growth in vitro and in xenografts, suggesting that it impacts neoplastic progression. Analysis of fibroblasts within premalignant and malignant skin lesions ranging from solar/actinic keratosis to squamous cell carcinoma revealed they express osteopontin. Given the stromal expression of osteopontin, we investigated how osteopontin impacts preneoplastic cell growth. We show that osteopontin promotes preneoplastic keratinocyte cellular proliferation and cell survival through the CD44 cell receptor and activation of the MAPK pathway. These data suggest that stromal-derived osteopontin impacts tumorigenesis by stimulating preneoplastic cell proliferation thus allowing expansion of initiated cells in early lesions.

Indexed as

Cell ProliferationCarcinoma, Squamous CellCell Cycle CheckpointsCell LineCell Transformation, NeoplasticCellular SenescenceCyclin-Dependent Kinase Inhibitor p16Cyclin-Dependent Kinase Inhibitor p21FibroblastsHumansKeratinocytesKeratosisMitogen-Activated Protein Kinase KinasesMutationNeoplasm ProteinsOsteopontinCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16Cyclin-Dependent Kinase Inhibitor p21Mitogen-Activated Protein Kinase KinasesNeoplasm ProteinsOsteopontin

Identifiers

PMID21673011
PMCPMC3685505
OpenAlexW2109413567

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.